Interim Director of HERU
- About
-
- Email Address
- g.scotland@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437181
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Graham is a Professor and leads the Assessment of Technologies theme in HERU. He joined HERU in 2004 and held a joint appointment between HERU and the Health Services Research Unit (HSRU) from 2012 to 2022. His current research interests span both model- and trial-based economic evaluation, with particular emphasis on the use decision analytic modelling alongside randomised controlled trials to maximise their value for informing health care decision making. Graham graduated from the University of Edinburgh in 1998 with BSc (Hons) in pharmacology, and following this undertook an MSc in Health Services and Public Health Research at the University of Aberdeen. After completing his MSc he worked at the Dugald Baird Centre for Research in Women's Health, University of Aberdeen, where he undertook research into economic aspects of maternal healthcare delivery in developing countries. Since his appointment in HERU he has gained over 19 years’ experience working in the area of health technology assessment. Graham also has an in interest in how the broader measures of value can incorporated in health technology assessment, and in 2012 completed a part-time PhD on methods for incorporating broader measures of value into economic evaluation in the area of reproductive healthcare.
- Publications
-
Page 1 of 10 Results 1 to 10 of 92
Effectiveness and cost-effectiveness of a peer-delivered, relational, harm reduction intervention to improve mental health, quality of life, and related outcomes, for people experiencing homelessness and substance use problems: protocol for the ‘SHARPS’ cluster randomised controlled trial
TrialsContributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1186/s13063-025-09364-x
User Preferences for the Use of AI in the National Breast Screening Programme: A Discrete Choice Experiment
Contributions to Conferences: PapersCost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: an economic evaluation based on data from the LENS trial
Diabetic Medicine, vol. 42, no. 9, e70098Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1111/dme.70098
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/0743b88e-2e6b-4e5f-9210-bd60fa05a866/download
Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial
Health Technology AssessmentContributions to Journals: ArticlesSotatercept for treating pulmonary arterial hypertension [ID6163]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned ReportsPatients and health care professionals’ perception of weekly prophylactic catheter washout in adults living with long-term catheters: Qualitative Study of the CATHETER II Trial
BMJ Open, vol. 15, no. 4, e087206Contributions to Journals: ArticlesCATHETER II: a randomised controlled trial comparing the clinical and cost effectiveness of various washout policies versus no washout policy in preventing catheter associated complications in adults living with long term catheters
BMJ Open, vol. 14, no. 12, e087203Contributions to Journals: ArticlesDirect and indirect costs of paediatric asthma in the UK: a cost analysis
Archives of Disease in Childhood, vol. 109, no. 9, pp. 724-729Contributions to Journals: ArticlesIvosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
National Institute for Health and Care Excellence (NICE). 20 pagesBooks and Reports: Commissioned Reports- [ONLINE] https://www.nice.org.uk/guidance/ta948
- [ONLINE] Page 214-316
- [ONLINE] https://www.nice.org.uk/guidance/ta948/evidence
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports